© 2020 MJH Life Sciences and OncLive. All rights reserved.
February 05, 2019
Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.
May 03, 2017
Matthew B. Yurgelun, MD, assistant professor of Medicine, Harvard Medical School, and a researcher at the Dana-Farber Cancer Institute, discusses germline testing in colorectal cancer.
September 22, 2016
Matthew B. Yurgelun, MD, Targeted Oncology, Yurgelun, Instructor in Medicine, Harvard Medical School, discusses a recent study which uncovered BRCA1 and BRCA2 mutations as possible risk markers for colorectal cancer.
August 26, 2016